Radium-223, An Alpha Emitter Treatment for Advanced Prostate Cancer Called A Breakthrough Treatment

In an interview about radium 223 with Medscape Medical News, Dr. Vapiwala pointed out that radium-223 is the first alpha-emitter to reach the market, and described it as a "breakthrough for radiopharmaceuticals" and "another breakthrough for prostate cancer," as it joins several other agents that have recently been approved for this disease. She characterized the [...]

Bayer Healthcare and Algeta Disappoint & Let Men with Advanced Prostate Cancer Down

The committee to start the early access clinical trials for drugs and treatments for men with advanced prostate cancer has been very hard at work. Based on the leadership and tenacity of Jan Manarite of the Prostate Cancer Research Institute (PCRI) we have managed to encourage, beg and cajole a number of pharmaceutical (pharma) companies [...]

From ASCO 2013 – Updated Analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) from the phase III randomized trial (ALSYMPCA).

Ra-223 (Alpharadin)is an alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range (< 100 ?m) alpha-particles. Currently it has been submitted to the FDA for approval, which we hope will happen by August 2013. In the phase 3, double-blind, randomized, multinational ALSYMPCA study, Ra-223 significantly improved overall survival (OS) in men with castrate resistant advanced prostate [...]

Two New Sites Available for Early Access to Alpharadin

There are now two new, additional sites added to the Early Access Trial of the investigational treatment known as Radium-233 or Alpharadin for men with castrate resistant prostate cancer with multiple bone metastases. This post contains the most up to date and accurate information, the clinical trials.gov site is NOT currently accurate. Additionally, there are [...]

Radium-223 (Alpharedin) Improves Survival in Men with Metastatic Prostate Cancer

At the October 28 meeting of the American Society for Radiation the final data from the ALSYMPCA trial were presented. The trial evaluated radium-223 (Alpharedin) in men with castrate-resistant prostate cancer that had spread to the bones. Alpharedin is part of a class of drugs called alpha-particle emitters that targets bone metastases. The good news [...]

Two Early Access Trials – 2 New sites for MDV-3100 & A New Early Access Trial for Radium-223 Chloride (Alpharedin)

There has been a lot of news in the area of early access for great drugs to treat advanced prostate cancer prior to the FDA’s approval. I have informed you about the Early Access Program for MDV-3100 in men with castrate resistant prostate cancer previously treated with a Docetaxel based chemotherapy agent. The latest news [...]

Alpharadin Data Updated for the Treatment of Men with Advanced Prostate Cancer that has Spread to Bone

Algeta announced that updated data from the phase III trial, ALSYMPCA, for its investigational drug Alpharadin (radium-223 dichloride). The data confirmed the overall survival of men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases using Alpharadin, compared to the interim analysis from June 2011. • Overall survival in Alpharadin arm increased by 44% • [...]

More Information on the Expanded Access Trial for Alpharadin (Radium-223)

Radium-223 Chloride (Alpharadin) is now available for the treatment of men with advanced prostate cancer who have symptomatic bone metastases (painful) and who are also castration-resistant (hormone-refractory). This is an expanded access program that will allow the use of Alpharadin prior to the formal FDA approval of the treatment. From the Clinical Trials Web Page [...]

Announcing Early Access To Alpharadin (Radium-233 Chloride)

I am interrupting the reviews of the AACR meeting to inform you of a very important piece of news. Men with advanced prostate cancer which is castrate resistant and who have 2 blaistic bone metastases may now have access to Alpharadin even though the FDA has not yet approved it in the United States! It [...]

Announcing A Compassionate Use Trial of Alpharadin

Radium-223 choride, also known as Alpharadin, has demonstrated a small but statistically significant survival benefit in men with symptomatic metastatic castrate resistant prostate cancer (mCRPC). My expectation is that it will be approved by the FDA some time later this year. Additionally, my hope is that it will also be approved Europe. To read more [...]